Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
Kestra Medical Technologies’ Chief Commercial Officer Alfred J. Ford Jr. reported selling a total of 27,632 Common Shares of KMTS across three transactions on July 30, July 31, and August 3, 2026. These sales, reported as open‑market or private transactions at weighted‑average prices between $22.17 and $24.28 per share, are described as nondiscretionary “sell‑to‑cover” trades made to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units.
Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported sales of 18,188 Common Shares in three transactions on July 30, July 31, and August 3, 2026. The footnotes state these were nondiscretionary sell to cover transactions executed solely to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, with each day’s sales priced at a weighted average within disclosed ranges.
Kestra Medical Technologies, Ltd. insider Traci S. Umberger, a director and officer, reported selling a total of 22229 Common Shares in three open-market or private transactions on July 30, July 31, and August 3, 2026. Footnotes state these were nondiscretionary sell-to-cover sales required to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units, executed at weighted-average prices within ranges from about $22.17 to $24.28 per share.
Kestra Medical Technologies president and CEO Brian Daniel Webster reported sales of 29,822 common shares of KMTS in three transactions on July 30, July 31 and August 3, 2026. The shares were sold at weighted average prices between $22.0577 and $24.1100 solely to cover tax withholding obligations from the vesting and settlement of restricted stock units.
Kestra Medical Technologies, Ltd. (KMTS) reports a planned sale of 13,015 shares of common stock through Merrill Lynch on or about 07/31/2026, to be traded on NASDAQ. These shares relate to performance share unit awards that vested on 07/17/2026 and were granted under the issuer’s equity compensation plan.
Alfred J. Ford previously sold 5,936 shares of common stock for $135,120.73 on 07/30/2026 and 8,681 shares for $196,284.58 on 07/31/2026.
Kestra Medical Technologies, Ltd. reported a planned sale of 5,391 shares of common stock through Merrill Lynch on the NASDAQ on 08/03/2026, with an indicated value of $128,312.27. The shares relate to performance share unit awards that vested on 07/17/2026 under the issuer’s equity compensation plan. In the prior three months, Vaseem Mahboob sold 3,980 shares for $90,560.62 on 07/30/2026 and 8,817 shares for $199,344.62 on 07/31/2026.
Kestra Medical Technologies, Ltd. (KMTS) has a selling securityholder, Traci Umberger, filing to sell common stock under Rule 144. The planned transaction lists 7,590 shares of common stock to be sold through Merrill Lynch on or after 08/03/2026, with an indicated value of $181,061.84 on NASDAQ.
The shares relate to a 07/17/2026 vesting of performance share unit awards granted as part of issuer equity compensation. Over the prior three months, Umberger sold 5,887 shares for $133,892.22 on 07/30/2026 and 8,752 shares for $197,837.19 on 07/31/2026.
Kestra Medical Technologies reports that an affiliate plans to sell 2,380 shares of common stock through Merrill Lynch on August 3, 2026 on NASDAQ, with an indicated aggregate market value of $56,551.44. These shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. The notice also lists prior sales by Timothy Moran of 4,117 shares for $93,758.64 on July 30, 2026 and 8,759 shares for $198,000.29 on July 31, 2026.
KESTRA MEDICAL TECHNOLOGIES, LTD. reports a planned sale of 13,017 shares of common stock through Merrill Lynch on July 31, 2026, listed on NASDAQ. These shares were acquired on July 17, 2026 as a performance stock issuance granted under the issuer’s equity compensation plan. Over the prior three months, reporting person Brian Webster sold multiple blocks of common shares, including 15,000-share transactions on April 15, May 15, June 15, and July 15, 2026, and additional sales of 7,857 and 8,948 shares on July 30 and July 31, 2026, respectively, each with stated aggregate sale values.
KESTRA MEDICAL TECHNOLOGIES, LTD. insider Alfred J Ford has filed to sell common stock under Rule 144. The planned sale covers 8,681 shares of common stock through Merrill Lynch, with an aggregate market value of $196,284.58, and is expected on July 31, 2026 on NASDAQ.
The shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. Over the past three months, Ford has already sold 5,936 shares for an aggregate sale price of $135,120.73.